

CITATION REPORT

List of articles citing

Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study

DOI: 10.1097/hjr.ob013e328336a150

European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, 491-501.

Source: <https://exaly.com/paper-pdf/48772616/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
291	Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010. 2010 , 5, 480-90		28
290	Premature onset of cardiovascular disease in HIV-infected individuals: the drugs and the virus. 2010 , 4, 675-692		4
289	[Peripheral arterial disease: a new challenge for HIV-infected patients]. 2010 , 135, 546-8		0
288	Regional fat deposition and cardiovascular risk in HIV infection: the FRAM study. 2011 , 23, 929-38		55
287	Cardiovascular disease and therapeutic drug-related cardiovascular consequences in HIV-infected patients. <i>American Journal of Cardiovascular Drugs</i> , 2011 , 11, 383-94	4	25
286	The metabolic syndrome in HIV. 2011 , 25, 479-86		22
285	Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study(*). <i>HIV Medicine</i> , 2011 , 12, 412-21	2.7	136
284	Cardiovascular risk assessment in persons with HIV infection in the developing world: comparing three risk equations in a cohort of HIV-infected Thais. <i>HIV Medicine</i> , 2011 , 12, 510-5	2.7	33
283	Accelerated coronary atherosclerosis after execution of percutaneous coronary intervention in patient with HIV/HCV coinfection: case report and review of the literature. 2011 , 12, 262-5		4
282	Noninvasive assessment of HIV-related coronary artery disease. <i>Current HIV/AIDS Reports</i> , 2011 , 8, 114-24.9		4
281	Management of dyslipidemia in HIV-infected patients. 2011 , 6, 447-462		20
280	HIV infection, aging and cardiovascular disease: epidemiology and prevention. 2011 , 8, 465-73		23
279	Antihypertensive drugs in patients treated with antiretrovirals. 2012 , 46, 703-9		22
278	Differences in lipid measurements by antiretroviral regimen exposure in cohorts from Asia and australia. 2012 , 2012, 246280		5
277	HIV replication and immune status are independent predictors of the risk of myocardial infarction in HIV-infected individuals. <i>Clinical Infectious Diseases</i> , 2012 , 55, 600-7	11.6	113
276	Working together in cardiovascular prevention: the common mission of the European Heart Journal and the European Journal of Preventive Cardiology. <i>European Journal of Preventive Cardiology</i> , 2012 , 19, 1217-26	3.9	4
275	Are HIV patients undertreated? Cardiovascular risk factors in HIV: results of the HIV-HEART study. <i>European Journal of Preventive Cardiology</i> , 2012 , 19, 267-74	3.9	61

274	Management of the metabolic effects of HIV and HIV drugs. 2011 , 8, 11-21		44
273	Nutrition and the HIV-associated lipodystrophy syndrome. 2012 , 25, 267-87		22
272	Cardiovascular disease in patients with HIV. 2012 , 7, 413-423		4
271	Clinical management considerations for dyslipidemia in HIV-infected individuals. 2012 , 124, 31-40		2
270	Cardiovascular risk estimation in 2012: lessons learned and applicability to the HIV population. 2012 , 205 Suppl 3, S362-7		54
269	Clinical outcomes of a combined HIV and renal clinic. 2012 , 5, 530-4		5
268	Underutilization of aspirin for primary prevention of cardiovascular disease among HIV-infected patients. <i>Clinical Infectious Diseases</i> , 2012 , 55, 1550-7	11.6	57
267	Impact of immunodepression and moderate alcohol consumption on coronary and other arterial disease events in an 11-year cohort of HIV-infected patients on antiretroviral therapy. 2012 , 2,		9
266	A dedicated clinic for HIV-positive individuals over 50 years of age: a multidisciplinary experience. <i>International Journal of STD and AIDS</i> , 2012 , 23, 546-52	1.4	24
265	Effect of darunavir on lipid profile in HIV-infected patients. 2012 , 13, 256-70		26
264	Changes in metabolic, inflammatory and coagulation biomarkers after HIV seroconversion--the Health in Men (HIM) Biomarker Substudy. 2013 , 18, 355-9		3
263	Reclassification of risk of death with the knowledge of D-dimer in a cohort of treated HIV-infected individuals. <i>Aids</i> , 2012 , 26, 1707-17	3.5	8
262	HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012 , 60 Suppl 1, S1-18	3.1	394
261	Coronary artery calcification in hemophilia A: no evidence for a protective effect of factor VIII deficiency on atherosclerosis. 2012 , 32, 799-804		44
260	Cardiovascular risk assessment for persons living with HIV. 2012 , 23, 134-45		4
259	[Cardiovascular risk and human immunodeficiency virus infection]. 2012 , 30, 515-6		1
258	Complications resulting from antiretroviral therapy for HIV infection. 2012 , 177-191		
257	The burden of diabetes and hyperlipidemia in treated HIV infection and approaches for cardiometabolic care. <i>Current HIV/AIDS Reports</i> , 2012 , 9, 206-17	5.9	66

256	Virological efficacy and safety of antiretroviral therapy-switch to atazanavir-based regimen: a review of the literature. 2012 , 13, 2355-67		1
255	Pharmacologic boosting of atazanavir in maintenance HIV-1 therapy: the COREYA propensity-score adjusted study. <i>PLoS ONE</i> , 2012 , 7, e49289	3.7	6
254	Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. <i>Journal of the International AIDS Society</i> , 2012 , 15, 17426	5.4	50
253	Cardiovascular disease and HIV infection. <i>Current HIV/AIDS Reports</i> , 2013 , 10, 199-206	5.9	110
252	Prevalence of cardiovascular diseases in HIV-infected outpatients: results from a prospective, multicenter cohort study. 2013 , 102, 203-13		46
251	Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons. <i>Clinical Infectious Diseases</i> , 2013 , 57, 112-21	11.6	45
250	Lipid profile of HIV-infected patients in relation to antiretroviral therapy: a review. 2013 , 59, 186-98		62
249	Serious Non-AIDS events: Immunopathogenesis and interventional strategies. 2013 , 10, 29		41
248	Metabolic syndrome in HIV-infected individuals: underlying mechanisms and epidemiological aspects. 2013 , 10, 32		86
247	Dyslipidemia, atherosclerosis and cardiovascular disease: an increasingly important triad in an aging population living with HIV. 2013 , 8, 1021-1034		8
246	Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States. 2013 , 31, 427-44		13
245	A comparison of the predicted risk for cardiovascular disease between HIV-infected and uninfected persons in Korea. 2013 , 45, 855-62		6
244	Lipid profile of HIV-infected patients in relation to antiretroviral therapy: a review. 2013 , 59, 186-198		1
243	The challenge of cardiovascular diseases in HIV-positive patients: it's time for redrawing the maps of cardiovascular risk?. 2013 , 67, 1-3		7
242	HIV and coronary heart disease: time for a better understanding. 2013 , 61, 511-23		194
241	Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013 , 63, 280-8	3.1	113
240	Mind the gap: difference between Framingham heart age and real age increases with age in HIV-positive individuals-a clinical cohort study. 2013 , 3, e003245		13
239	Long-term predictive value of the Framingham Risk Score for Stroke in HIV-positive vs HIV-negative men. 2013 , 81, 2094-102		38

238	Transgenic mouse model with deficient mitochondrial polymerase exhibits reduced state IV respiration and enhanced cardiac fibrosis. 2013 , 93, 151-8		14
237	Enhanced effector function of CD8(+) T cells from healthy controls and HIV-infected patients occurs through thrombin activation of protease-activated receptor 1. 2013 , 207, 638-50		27
236	HIV infection and the risk of acute myocardial infarction. 2013 , 173, 614-22		832
235	Human immunodeficiency virus and menopause. 2013 , 20, 983-90		26
234	Persistently elevated serum interleukin-6 predicts mortality among adults receiving combination antiretroviral therapy in Botswana: results from a clinical trial. 2013 , 29, 993-9		32
233	Association of hepatitis C with markers of hemostasis in HIV-infected and uninfected women in the women@teragency HIV study (WIHS). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013 , 62, 301-10	3.1	6
232	A review of cardiovascular and renal function monitoring: a consideration of older adults with HIV. 2013 , 5, 263-74		2
231	Screening and management of cardiovascular disease in Australian adults with HIV infection. 2013 , 10, 495-501		13
230	HIV, vascular and aging injuries in the brain of clinically stable HIV-infected adults: a (1)H MRS study. <i>PLoS ONE</i> , 2013 , 8, e61738	3.7	82
229	HIV Infection and Cardiovascular Disease. 2013 , 2013, 1-3		78
228	Cardiovascular risk assessment: a comparison of the Framingham, PROCAM, and DAD equations in HIV-infected persons. 2013 , 2013, 969281		38
227	Risk of coronary heart disease among HIV-infected patients: a multicenter study in Brazil. 2013 , 2013, 163418		3
226	Plasma lipidomic profiling of treated HIV-positive individuals and the implications for cardiovascular risk prediction. <i>PLoS ONE</i> , 2014 , 9, e94810	3.7	19
225	International Congress of Drug Therapy in HIV Infection 2-6 November 2014, Glasgow, UK. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19856	5.4	
224	Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system. 2014 , 53, 891-906		51
223	Heart failure in HIV infection: focus on the role of atherosclerosis. 2014 , 29, 174-9		9
222	How to identify HIV-infected individuals at risk for atherosclerotic events?. <i>Aids</i> , 2014 , 28, 2153-5	3.5	
221	Prehypertension, hypertension, and the risk of acute myocardial infarction in HIV-infected and -uninfected veterans. <i>Clinical Infectious Diseases</i> , 2014 , 58, 121-9	11.6	74

220	Cardiovascular disease risk in an aging HIV population: not just a question of biology. 2014 , 9, 346-54		31
219	Plasma plasminogen activator inhibitor-1 predicts myocardial infarction in HIV-1-infected individuals. <i>Aids</i> , 2014 , 28, 1171-9	3.5	17
218	HIV infection and cardiovascular disease. 2014 , 35, 1373-81		144
217	Diagnosis of subclinical atherosclerosis in HIV-infected patients: higher accuracy of the D:A:D risk equation over Framingham and SCORE algorithms. <i>European Journal of Preventive Cardiology</i> , 2014 , 21, 739-48	3.9	21
216	Aggregate risk of cardiovascular disease among adolescents perinatally infected with the human immunodeficiency virus. 2014 , 129, 1204-12		31
215	Prevalence, treatment, and control of dyslipidemia and hypertension in 4278 HIV outpatients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014 , 66, 370-7	3.1	36
214	Inflammatory co-morbidities in HIV+ individuals: learning lessons from healthy ageing. <i>Current HIV/AIDS Reports</i> , 2014 , 11, 20-34	5.9	59
213	Cardiovascular disease in human immunodeficiency virus. 2014 , 44, 315-24		12
212	Risk of coronary heart disease in patients with HIV infection. 2014 , 11, 728-41		73
211	Dyslipidemia and cardiovascular risk in human immunodeficiency virus infection. 2014 , 43, 665-84		24
210	Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations. <i>HIV Medicine</i> , 2014 , 15, 595-603	2.7	38
209	HIV-associated neurocognitive disorder in Australia: a case of a high-functioning and optimally treated cohort and implications for international neuroHIV research. <i>Journal of NeuroVirology</i> , 2014 , 20, 258-68	3.9	53
208	Metabolic syndrome, diabetes, and cardiovascular risk in HIV. <i>Current HIV/AIDS Reports</i> , 2014 , 11, 271-8	5.9	57
207	Determinants of developing widened spatial QRS-T angle in HIV-infected individuals: results from the Strategies for Management of Antiretroviral Therapy [SMART] Study. 2014 , 47, 264-71		3
206	Menthol cigarettes and the cardiovascular risks of people living with HIV. 2014 , 25, 427-35		10
205	Physical Activity Affects Brain Integrity in HIV+ Individuals. 2015 , 21, 880-9		21
204	Assessment of cardiovascular risk factors in people with HIV infection treated with ART in rural South Africa: a cross sectional study. 2015 , 12, 42		29
203	Effect of Cumulating Exposure to Abacavir on the Risk of Cardiovascular Disease Events in Patients From the Swiss HIV Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015 , 69, 413-21	3.1	61

202	The Additive Value of Femoral Ultrasound for Subclinical Atherosclerosis Assessment in a Single Center Cohort of 962 Adults, Including High Risk Patients with Rheumatoid Arthritis, Human Immunodeficiency Virus Infection and Type 2 Diabetes Mellitus. <i>PLoS ONE</i> , 2015 , 10, e0132307	3.7	21
201	Cardiovascular Complications of HIV-Associated Immune Dysfunction. 2015 , 2015, 302638		12
200	Diabetes and Dyslipidemia in Treated Human Immunodeficiency Virus Infection and Approaches for Cardiometabolic Care. 2015 , 441-469		
199	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. 2015 , 9, S1-122.e1		293
198	Cardiovascular risk factors and lifetime risk estimation in HIV-infected patients under antiretroviral treatment in Spain. 2015 , 16, 57-65		13
197	Management of lipid disorders in patients living with HIV. 2015 , 55, 957-74		26
196	Metabolic abnormalities and cardiovascular risk in HIV-infected cohort of patients treated with protease inhibitors. 2015 , 14, 22-27		
195	[Consensus statement on metabolic disorders and cardiovascular risks in patients with human immunodeficiency virus]. 2015 , 33, 40.e1-40.e16		6
194	Extrahepatic manifestations of hepatitis C infection: navigating CHASM. <i>Current HIV/AIDS Reports</i> , 2015 , 12, 353-61	5.9	32
193	Comparison of four international cardiovascular disease prediction models and the prevalence of eligibility for lipid lowering therapy in HIV infected patients on antiretroviral therapy. 2015 , 56, 14-23		18
192	Novel Biomarkers of Cardiac Stress, Cardiovascular Dysfunction, and Outcomes in HIV-Infected Individuals. 2015 , 3, 591-9		44
191	Atherosclerosis in HIV patients: a different disease or more of the same?. <i>Atherosclerosis</i> , 2015 , 240, 333-4	3.1	2
190	Lipid management in human immunodeficiency virus. 2015 , 33, 277-98		1
189	Metabolic disorders and cardiovascular risk in treatment-naïve HIV-infected patients of sub-saharan origin starting antiretrovirals: impact of westernized lifestyle. 2015 , 31, 384-92		12
188	Heart failure in patients with human immunodeficiency virus: a review of the literature. <i>Journal of Cardiovascular Medicine</i> , 2015 , 16, 383-9	1.9	13
187	Baseline cardiovascular risk in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. <i>HIV Medicine</i> , 2015 , 16 Suppl 1, 46-54	2.7	19
186	[In Process Citation]. 2015 , 157 Suppl 2, 29-33		
185	Risk of Cardiovascular Disease in an Aging HIV Population: Where Are We Now?. <i>Current HIV/AIDS Reports</i> , 2015 , 12, 375-87	5.9	49

184	Cardiovascular disease associated with human immunodeficiency virus: A review. 2015 , 34, 479-491		3
183	Cardiovascular disease associated with human immunodeficiency virus: a review. 2015 , 34, 479-91		7
182	The value of flow cytometry in the measurement of platelet activation and aggregation in human immunodeficiency virus infection. 2015 , 26, 250-7		8
181	Changes in coronary heart disease risk profiles of HIV patients in Zimbabwe over 9 months: a follow-up study. 2016 , 8, 165-174		1
180	Neutrophil to Lymphocyte Ratio and Cardiovascular Disease Incidence in HIV-Infected Patients: A Population-Based Cohort Study. <i>PLoS ONE</i> , 2016 , 11, e0154900	3.7	11
179	Dyslipidemias and Elevated Cardiovascular Risk on Lopinavir-Based Antiretroviral Therapy in Cambodia. <i>PLoS ONE</i> , 2016 , 11, e0160306	3.7	14
178	Incidence of Diabetes Mellitus and Obesity and the Overlap of Comorbidities in HIV+ Hispanics Initiating Antiretroviral Therapy. <i>PLoS ONE</i> , 2016 , 11, e0160797	3.7	11
177	Statins to improve cardiovascular outcomes in treated HIV infection. <i>Current Opinion in Infectious Diseases</i> , 2016 , 29, 1-9	5.4	22
176	HIV, highly active antiretroviral therapy and the heart: a cellular to epidemiological review. <i>HIV Medicine</i> , 2016 , 17, 411-24	2.7	28
175	Cardiovascular risk prediction in HIV-infected patients: comparing the Framingham, atherosclerotic cardiovascular disease risk score (ASCVD), Systematic Coronary Risk Evaluation for the Netherlands (SCORE-NL) and Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) risk prediction	2.7	35
174	Soluble Levels of Receptor for Advanced Glycation Endproducts (RAGE) and Progression of Atherosclerosis in Individuals Infected with Human Immunodeficiency Virus: ACTG NWCS 332. 2016 , 39, 1354-62		4
173	Cardiovascular disease risk scores Relationship to subclinical cardiovascular disease among HIV-infected and HIV-uninfected men. <i>Aids</i> , 2016 , 30, 2075-84	3.5	17
172	What happens to cardiovascular system behind the undetectable level of HIV viremia?. 2016 , 13, 21		23
171	Vascular age calculation and equivalent risk factors in HIV-infected patients obtained from the D:A:D risk equation. <i>European Journal of Preventive Cardiology</i> , 2016 , 23, 1903-1908	3.9	2
170	British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. <i>HIV Medicine</i> , 2016 , 17 Suppl 4, s2-s104	2.7	63
169	Smoking and projected cardiovascular risk in an HIV-positive Asian regional cohort. <i>HIV Medicine</i> , 2016 , 17, 542-9	2.7	8
168	Atherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy. <i>Current HIV/AIDS Reports</i> , 2016 , 13, 297-308	5.9	15
167	Cardiovascular Disease Risk Prediction in the HIV Outpatient Study. <i>Clinical Infectious Diseases</i> , 2016 , 63, 1508-1516	11.6	75

166	Cardiovascular disease risk assessment in HIV: navigating data-sparse zones. 2016 , 102, 1157-8		4
165	Longitudinal analysis of the associations between antiretroviral therapy, viraemia and immunosuppression with lipid levels: the D:A:D study. 2016 , 21, 495-506		15
164	The cardiovascular risk management for people living with HIV in Europe: how well are we doing?. <i>Aids</i> , 2016 , 30, 2505-2518	3.5	25
163	Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration. 2016 , 14, 61		84
162	Human Immunodeficiency Virus as a Chronic Disease: Evaluation and Management of Nonacquired Immune Deficiency Syndrome-Defining Conditions. <i>Open Forum Infectious Diseases</i> , 2016 , 3, ofw097	1	24
161	Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. <i>HIV Medicine</i> , 2016 , 17, 255-68	2.7	88
160	Plasma Efavirenz Concentrations Are Associated With Lipid and Glucose Concentrations. 2016 , 95, e2385		24
159	Lipid Management in Human Immunodeficiency Virus. 2016 , 45, 141-69		5
158	Short Communication: Do Cytomegalovirus Antibody Levels Associate with Age-Related Syndromes in HIV Patients Stable on Antiretroviral Therapy?. 2016 , 32, 567-72		23
157	Patterns of Cardiovascular Mortality for HIV-Infected Adults in the United States: 1999 to 2013. 2016 , 117, 214-20		168
156	Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis. 2016 , 37, 3600-3609		29
155	Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients. 2016 , 71, 1451-65		24
154	HIV Infection and Primary Prevention of Cardiovascular Disease: Lights and Shadows in the HAART Era. <i>Progress in Cardiovascular Diseases</i> , 2016 , 58, 565-76	8.5	30
153	High Prevalence of Metabolic Syndrome and Cardiovascular Disease Risk Among People with HIV on Stable ART in Southwestern Uganda. 2016 , 30, 4-10		50
152	Coronary artery disease risk reduction in HIV-infected persons: a comparative analysis. 2016 , 28, 475-82		15
151	An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. <i>European Journal of Preventive Cardiology</i> , 2016 , 23, 214-23	3.9	127
150	Statin Use With the ATP III Guidelines Compared to the 2013 ACC/AHA Guidelines in HIV Primary Care Patients. 2017 , 30, 64-69		6
149	Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. 2017 , 4, e154-e160		63

148	Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1-Infected Adults. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017 , 75, 61-66	3.1	52
147	Cardiovascular risk in advanced naïve HIV-infected patients starting antiretroviral therapy: Comparison of three different regimens - PREVALEAT II cohort. <i>Atherosclerosis</i> , 2017 , 263, 398-404	3.1	14
146	Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	31
145	Association of Macrophage Inflammation Biomarkers With Progression of Subclinical Carotid Artery Atherosclerosis in HIV-Infected Women and Men. 2017 , 215, 1352-1361		65
144	Cardiovascular disease in patients with HIV. 2017 , 27, 558-563		30
143	Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients. 2017 , 29, 299-307		5
142	The Use of Primary Prevention Statin Therapy in Those Predisposed to Atherosclerosis. 2017 , 19, 48		10
141	Are we successfully managing cardiovascular disease in people living with HIV?. 2017 , 12, 594-603		10
140	Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. 2017 , 390, 2063-2072		169
139	Serum suppression of tumorigenicity 2 level is an independent predictor of all-cause mortality in HIV-infected patients. <i>Aids</i> , 2017 , 31, 2355-2365	3.5	3
138	Comparison of the ACC/AHA and Framingham algorithms to assess cardiovascular risk in HIV-infected patients. 2017 , 21, 577-580		8
137	Subclinical atherosclerosis in low Framingham risk HIV patients. 2017 , 47, 591-599		10
136	Skin advanced glycation end products in HIV infection are increased and predictive of development of cardiovascular events. <i>Aids</i> , 2017 , 31, 241-246	3.5	5
135	Relationship between estimated cardiovascular disease risk and insulin resistance in a black African population living with HIV: a cross-sectional study from Cameroon. 2017 , 7, e016835		9
134	Epidemiology of ischemic heart disease in HIV. 2017 , 12, 540-547		24
133	Cardiovascular prevention in HIV-positive individuals on antiretroviral therapy.. The paradigm shift has already happened: Is it time to wake up and realise it?. <i>European Journal of Preventive Cardiology</i> , 2017 , 24, 1381-1382	3.9	
132	Change in urinary cortisol excretion mediates the effect of angry/hostile mood on 9 month diastolic blood pressure in HIV+ adults. 2017 , 40, 620-630		2
131	A pilot study of brisk walking in sedentary combination antiretroviral treatment (cART)- treated patients: benefit on soluble and cell inflammatory markers. <i>BMC Infectious Diseases</i> , 2017 , 17, 61	4	27

130	Cardiovascular disease risk among Chinese antiretroviral-naïve adults with advanced HIV disease. <i>BMC Infectious Diseases</i> , 2017 , 17, 287	4	18
129	Antiretroviral therapy related adverse effects: Can sub-Saharan Africa cope with the new "test and treat" policy of the World Health Organization?. 2017 , 6, 24		24
128	Mortal allies: human immunodeficiency virus and noncommunicable diseases. 2017 , 12, 148-156		9
127	Ideal Cardiovascular Health and Carotid Atherosclerosis in a Mixed Cohort of HIV-Infected and Uninfected Ugandans. 2017 , 33, 49-56		26
126	Screening and risk assessment for coronary artery disease in HIV infection: an unmet need. <i>HIV Medicine</i> , 2017 , 18, 292-299	2.7	8
125	Cardiac Disease Associated with Human Immunodeficiency Virus Infection. 2017 , 35, 59-70		15
124	Metabolic disorders and cardiovascular risk in people living with HIV/AIDS without the use of antiretroviral therapy. 2017 , 50, 598-606		14
123	Resveratrol Co-Treatment Attenuates the Effects of HIV Protease Inhibitors on Rat Body Weight and Enhances Cardiac Mitochondrial Respiration. <i>PLoS ONE</i> , 2017 , 12, e0170344	3.7	8
122	High correlation between Framingham equations with BMI and with lipids to estimate cardiovascular risks score at baseline in HIV-infected adults in the Temprano trial, ANRS 12136 in Côte d'Ivoire. <i>PLoS ONE</i> , 2017 , 12, e0177440	3.7	8
121	Predictive factors and prevalence of microalbuminuria in HIV-infected patients: a cross-sectional analysis. 2017 , 18, 255		7
120	Factors affecting affect cardiovascular health in Indonesian HIV patients beginning ART. 2017 , 14, 52		14
119	Assessment of the agreement between the Framingham and DAD risk equations for estimating cardiovascular risk in adult Africans living with HIV infection: a cross-sectional study. 2017 , 3, 12		7
118	Platelet Transcriptome Profiling in HIV and ATP-Binding Cassette Subfamily C Member 4 (ABCC4) as a Mediator of Platelet Activity. 2018 , 3, 9-22		18
117	Cardiovascular markers of inflammation and serum lipid levels in HIV-infected patients with undetectable viremia. 2018 , 8, 6113		5
116	Cardiovascular Risk Prediction Functions Underestimate Risk in HIV Infection. 2018 , 137, 2203-2214		97
115	Metabolites predict cardiovascular disease events in persons living with HIV: a pilot case-control study. 2018 , 14, 1		6
114	Differences by HIV serostatus in coronary artery disease severity and likelihood of percutaneous coronary intervention following stress testing. 2018 , 25, 872-883		4
113	Cardiovascular disease in women living with HIV: A narrative review. 2018 , 108, 58-70		13

112	HIV-Associated Cardiovascular Disease. 2018 ,		1
111	The dawn of precision medicine in HIV: state of the art of pharmacotherapy. 2018 , 19, 1581-1595		8
110	The HIV patient profile in 2013 and 2003: Results from the Greek AMACS cohort. <i>PLoS ONE</i> , 2018 , 13, e0203601	3.7	2
109	Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort. <i>Aids</i> , 2018 , 32, 2405-2416	3.5	43
108	Metabolic Syndrome Among Antiretroviral Therapy-Naive Versus Experienced HIV-Infected Patients Without Preexisting Cardiometabolic Disorders in Western Kenya. 2018 , 32, 215-222		13
107	Global Burden of Atherosclerotic Cardiovascular Disease in People Living With HIV: Systematic Review and Meta-Analysis. 2018 , 138, 1100-1112		248
106	Prevalence and associated risk factors of peripheral artery disease in virologically suppressed HIV-infected individuals on antiretroviral therapy in Kwara state, Nigeria: a cross sectional study. <i>BMC Public Health</i> , 2019 , 19, 1143	4.1	6
105	Assessment of Biventricular Function by Three-Dimensional Speckle Tracking Echocardiography in Adolescents and Young Adults with Human Immunodeficiency Virus Infection: A Pilot Study. 2019 , 144, 101-111		4
104	Cardiovascular risk in HIV-infected individuals: A comparison of three risk prediction algorithms. 2019 , 38, 463-470		0
103	Age-specific associations between HIV infection and carotid artery intima-media thickness in China: a cross-sectional evaluation of baseline data from the CHART cohort. 2019 , 6, e860-e868		16
102	Time to change cardiovascular prevention in people with HIV. 2019 , 6, e811-e812		1
101	Cardiovascular risk in HIV-infected individuals: A comparison of three risk prediction algorithms. 2019 , 38, 463-470		10
100	Cardiovascular adverse events during treatment with darunavir-based regimens in an Italian observational study. <i>Drug Design, Development and Therapy</i> , 2019 , 13, 1667-1685	4.4	1
99	Statins and aspirin in the prevention of cardiovascular disease among HIV-positive patients between controversies and unmet needs: review of the literature and suggestions for a friendly use. 2019 , 16, 11		9
98	Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association. 2019 , 140, e98-e124		176
97	Risk Prediction. 2019 , 13-22		
96	Diagnosis and Management of Dyslipidemia. 2019 , 23-45		
95	Diabetes, Prediabetes, and Metabolic Syndrome Among People Living with HIV. 2019 , 55-75		

94	Noninvasive Cardiovascular Imaging: Emergence of a Powerful Tool for Early Identification of Cardiovascular Risk in People Living With HIV. 2019 , 35, 260-269		2
93	Cardiovascular disease incidence projections in the TREAT Asia HIV Observational Database (TAHOD). 2019 , 24, 271-279		0
92	Evaluation of Vascular Event Risk while on Long-term Anti-retroviral Suppressive Therapy [EVERLAST]: Protocol for a prospective observational study. 2019 , 15, 100189		7
91	Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back. <i>Aids</i> , 2019 , 33, 2387-2391	3.5	22
90	Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe. <i>Aids</i> , 2019 , 33, 2013-2024	3.5	11
89	Predictive Performance of Cardiovascular Disease Risk Prediction Algorithms in People Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019 , 81, 562-571	3.1	15
88	In-hospital and long-term outcomes of HIV-positive patients undergoing PCI according to kind of stent: a meta-analysis. <i>Journal of Cardiovascular Medicine</i> , 2019 , 20, 321-326	1.9	3
87	Factors Associated With Excess Myocardial Infarction Risk in HIV-Infected Adults: A Systematic Review and Meta-analysis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019 , 81, 224-230	3.1	19
86	Excess heart age in adult outpatients in routine HIV care. <i>Aids</i> , 2019 , 33, 1935-1942	3.5	3
85	Associations between lipids and subclinical coronary atherosclerosis. <i>Aids</i> , 2019 , 33, 1053-1061	3.5	1
84	Cardiovascular disease and diabetes in HIV-positive and HIV-negative gay and bisexual men over the age of 55 years in Australia: insights from the Australian Positive & Peers Longevity Evaluation Study. <i>HIV Medicine</i> , 2019 , 20, 121-130	2.7	6
83	Vascular cognitive impairment and HIV-associated neurocognitive disorder: a new paradigm. <i>Journal of NeuroVirology</i> , 2019 , 25, 710-721	3.9	33
82	Cardiovascular Risk Assessment Varies Widely by Calculator and Race/Ethnicity in a Majority Latinx Cohort Living with HIV. <i>Journal of Immigrant and Minority Health</i> , 2020 , 22, 323-335	2.2	2
81	Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofz472	1	11
80	Implementation of Cholesterol-Lowering Therapy to Reduce Cardiovascular Risk in Persons Living with HIV. <i>Cardiovascular Drugs and Therapy</i> , 2020 , 1	3.9	
79	Coronary Artery Disease in Patients with HIV Infection: An Update. <i>American Journal of Cardiovascular Drugs</i> , 2021 , 21, 411-417	4	5
78	Evolution of comorbidities in people living with HIV between 2004 and 2014: cross-sectional analyses from ANRS CO3 Aquitaine cohort. <i>BMC Infectious Diseases</i> , 2020 , 20, 850	4	7
77	[Cardiovascular risk calculators for people living with human immunodeficiency virus]. <i>Hipertension Y Riesgo Vascular</i> , 2020 , 37, 181-193	0.5	

76	Statins for atherosclerotic cardiovascular disease prevention in people living with HIV in Thailand: a cost-effectiveness analysis. <i>Journal of the International AIDS Society</i> , 2020 , 23 Suppl 1, e25494	5.4	4
75	Are Physical Fitness and CRP Related to Framingham Risk Score in HIV+ Adults?. <i>American Journal of Lifestyle Medicine</i> , 2022 , 16, 229-240	1.9	
74	The prevalence of selected non-communicable disease risk factors among HIV patients on anti-retroviral therapy in Bushbuckridge sub-district, Mpumalanga province. <i>BMC Public Health</i> , 2020 , 20, 247	4.1	6
73	Fluoride-based molecular imaging of coronary atherosclerosis in HIV infected patients. <i>Atherosclerosis</i> , 2020 , 297, 127-135	3.1	9
72	Prevention of stroke in people living with HIV. <i>Progress in Cardiovascular Diseases</i> , 2020 , 63, 160-169	8.5	8
71	Cardiovascular disease in HIV patients: recent advances in predicting and managing risk. <i>Expert Review of Anti-Infective Therapy</i> , 2020 , 18, 677-688	5.5	4
70	Cardiovascular risk factors in HIV infected individuals: Comparison with general adult control population in Greece. <i>PLoS ONE</i> , 2020 , 15, e0230730	3.7	9
69	Utilization of absolute monocyte counts to predict cardiovascular events in people living with HIV. <i>HIV Medicine</i> , 2021 , 22, 314-320	2.7	0
68	Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents. <i>Aids</i> , 2021 , 35, 869-882	3.5	5
67	Incorporating Frailty Into the Pooled Cohort Equations to Predict Cardiovascular Disease Among Persons With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021 , 87, 971-977	3.1	1
66	Cost-effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States. <i>Journal of the International AIDS Society</i> , 2021 , 24, e25690	5.4	1
65	The Prevalence and Risk Factors for Peripheral Arterial Disease in Adults Living With Human Immunodeficiency Virus. <i>International Journal of Lower Extremity Wounds</i> , 2021 , 15347346211009404	1.6	
64	Carotid atherosclerosis in virologically suppressed HIV patients: comparison with a healthy sample and prediction by cardiovascular risk equations. <i>HIV Medicine</i> , 2021 , 22, 581-591	2.7	
63	Prediction of future cardiovascular events by Framingham, SCORE and asCVD risk scores is less accurate in HIV-positive individuals from the HIV-HEART Study compared with the general population. <i>HIV Medicine</i> , 2021 , 22, 732-741	2.7	1
62	Incidence of acute ischemic cerebrovascular events in a cohort of HIV-infected patients. <i>Acta Neurologica Belgica</i> , 2021 , 1	1.5	1
61	Assessing Cardiovascular Risk in People Living with HIV: Current Tools and Limitations. <i>Current HIV/AIDS Reports</i> , 2021 , 18, 271-279	5.9	4
60	Proportion of patients eligible for statin therapy substantially varies between different cardiovascular disease risk calculators and guidelines used. <i>International Journal of STD and AIDS</i> , 2021 , 32, 1188-1195	1.4	0
59	The data-collection on adverse effects of anti-HIV drugs (D:A:D) model for predicting cardiovascular events: External validation in a diverse cohort of people living with HIV. <i>HIV Medicine</i> , 2021 , 22, 936-943	2.7	0

58	Myocardial Fibrosis and Inflammation by CMR Predict Cardiovascular Outcome in People Living With HIV. <i>JACC: Cardiovascular Imaging</i> , 2021 , 14, 1548-1557	8.4	7
57	Coronary Artery Calcification and Plaque Characteristics in People Living With HIV: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2021 , 10, e019291	6	2
56	Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV. <i>BMC Infectious Diseases</i> , 2021 , 21, 910	4	0
55	Dyslipidemia in HIV-Infected Patients. <i>Contemporary Endocrinology</i> , 2015 , 155-176	0.3	1
54	Dyslipidemia in HIV. 2015 , 241-255		1
53	Association Between Depressive Symptom Patterns and Clinical Profiles Among Persons Living with HIV. <i>AIDS and Behavior</i> , 2018 , 22, 1411-1422	4.3	14
52	Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment-Experienced People Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021 , 73, e2323-e2333	11.6	5
51	Additive and Synergistic Cardiovascular Disease Risk Factors and HIV Disease Markers Effects on White Matter Microstructure in Virally Suppressed HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020 , 84, 543-551	3.1	1
50	An inducible cell-cell fusion system with integrated ability to measure the efficiency and specificity of HIV-1 entry inhibitors. <i>PLoS ONE</i> , 2011 , 6, e26731	3.7	23
49	Silent ischemic heart disease and pericardial fat volume in HIV-infected patients: a case-control myocardial perfusion scintigraphy study. <i>PLoS ONE</i> , 2013 , 8, e72066	3.7	28
48	Association of residual plasma viremia and intima-media thickness in antiretroviral-treated patients with controlled human immunodeficiency virus infection. <i>PLoS ONE</i> , 2014 , 9, e113876	3.7	11
47	Cardiovascular risk and response to lipid lowering therapy in patients with HIV infection according to different recommendations. <i>PLoS ONE</i> , 2020 , 15, e0244675	3.7	0
46	C-Reactive Protein as an Independent Cardiovascular Risk Predictor in HIV+ Patients: A Focused Review of Published Studies. <i>Journal of Clinical Medicine Research</i> , 2017 , 9, 891-899	2.9	11
45	Integrated Public Health and Health Service Delivery for Noncommunicable Diseases and Comorbid Infectious Diseases and Mental Health. 2017 , 287-303		2
44	The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile. <i>Drug Design, Development and Therapy</i> , 2020 , 14, 5515-5520	4.4	8
43	Cardiovascular Risk Assessment in People Living With HIV: A Systematic Review and Meta-Analysis of Real-Life Data. <i>Current HIV Research</i> , 2020 , 18, 5-18	1.3	9
42	Epidemiology and management of antiretroviral-associated cardiovascular disease. <i>Open AIDS Journal</i> , 2015 , 9, 23-37	0.6	18
41	Effects of Therapy with Maraviroc on the Carotid Intima Media Thickness in HIV-1/HCV Co-infected Patients. <i>In Vivo</i> , 2017 , 31, 125-131	2.3	11

40	The association between alcohol use and cardiovascular disease among people living with HIV: a systematic review. <i>American Journal of Drug and Alcohol Abuse</i> , 2015 , 41, 479-88	3.7	20
39	Cardiovascular disease in human immunodeficiency virus infected patients: A true or perceived risk?. <i>World Journal of Cardiology</i> , 2015 , 7, 633-44	2.1	30
38	Cardiovascular risk evaluation of HIV-positive patients in a case-control study: comparison of the D:A:D and Framingham equations. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19515	5.4	9
37	Cardiovascular risk score associations with frailty in men and women with or at risk for HIV.. <i>Aids</i> , 2022 , 36, 237-347	3.5	0
36	Coronary artery plaque progression and cardiovascular risk scores in men with and without HIV-infection. <i>Aids</i> , 2021 , 36,	3.5	0
35	Encyclopedia of AIDS. 2016 , 1-9		
34	Encyclopedia of AIDS. 2018 , 477-485		
33	[CME: Dyslipidemia and Cardiovascular Risk in HIV Infected Patients]. <i>Praxis</i> , 2019 , 108, 451-458	0.1	
32	Limited Utility of Cardiovascular Risk Scores for People Living with HIV in Malawi.		0
31	HIV and Dyslipidemia. <i>Contemporary Cardiology</i> , 2021 , 431-466	0.1	
30	The prevalence of selected non-communicable disease risk factors among HIV patients on anti-retroviral therapy in Bushbuckridge Sub-district, Mpumalanga province.		
29	HIV/AIDS. 2021 , 361-368		
28	Association of Lower Adiponectin Plasma Levels, Increased Age and Smoking with Subclinical Atherosclerosis in Patients with HIV-1 Infection. <i>Current HIV Research</i> , 2020 , 18, 292-306	1.3	1
27	Atherosclerosis is associated with a higher risk of hepatic steatosis in HIV-infected patients. <i>Journal of Preventive Medicine and Hygiene</i> , 2017 , 58, E219-E224	1.4	1
26	Subclinical Carotid Atherosclerosis and Reduced DAD Score for Cardiovascular Risk Stratification in HIV-Positive Patients. <i>Arquivos Brasileiros De Cardiologia</i> , 2020 , 114, 68-75	1.2	0
25	Obesity in young South African women living with HIV: A cross-sectional analysis of risk factors for cardiovascular disease. <i>PLoS ONE</i> , 2021 , 16, e0255652	3.7	3
24	Circulating CD4+ TEMRA and CD4+ CD28- T cells and incident diabetes among persons with and without HIV. <i>Aids</i> , 2021 ,	3.5	0
23	Cardiovascular risk prediction equations underestimate risk in people living with HIV: Comparison and cut-point redefinition for 19 cardiovascular risk equations.. <i>Current HIV Research</i> , 2022 ,	1.3	

22	Increased Circulating Levels of Growth Differentiation Factor 15 in Association with Metabolic Disorders in People Living with HIV Receiving Combined Antiretroviral Therapy.. <i>Journal of Clinical Medicine</i> , 2022 , 11,	5.1	0
21	Brain aging and cardiovascular factors in HIV: A longitudinal volume and shape MRI study.. <i>Aids</i> , 2022 ,	3.5	0
20	Gut microbiota from Mexican patients with metabolic syndrome and HIV infection: an inflammatory profile.. <i>Journal of Applied Microbiology</i> , 2022 ,	4.7	2
19	Structural equation model of psychological constructs of transtheoretical model, motives for physical activity, and amount of physical activity among people with type 2 diabetes mellitus in Malaysia.. <i>PLoS ONE</i> , 2022 , 17, e0266104	3.7	
18	Biomarkers to predict cardiovascular disease in people living with HIV. <i>Current Opinion in Infectious Diseases</i> , 2021 , 35,	5.4	2
17	Cardiovascular risk assessment in people living with HIV compared to the general population. <i>European Journal of Preventive Cardiology</i> , 2021 ,	3.9	0
16	The prevalence of Type 2 Diabetes among people living with HIV in Georgia.		
15	Association of inflammatory biomarkers and cardiovascular risk scores in an Italian cohort of HIV positive patient undergoing antiretroviral therapy. <i>Current HIV Research</i> , 2022 , 20,	1.3	
14	Prevalence and determinants of non-communicable diseases including depression among HIV patients on antiretroviral therapy in Dar es Salaam, Tanzania. <i>Tropical Medicine and International Health</i> ,	2.3	
13	Cardiovascular Disease. 2021 , 435-451		
12	Comparison of Three Cardiovascular Risk Scores among HIV-Infected Patients in Korea: The Korea HIV/AIDS Cohort Study. 54,		
11	Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China. 2022 , 91, S8-S15		0
10	Weight Gain and Lipid Profile Changes in Koreans with Human Immunodeficiency Virus undergoing Integrase Strand Transfer Inhibitor-Based Regimens. 2022 , 54, 419		1
9	Comparative performance of cardiovascular risk prediction models in people living with HIV. 2022 , 23,		0
8	PREMATURE AGING AND CARDIOVASCULAR DISEASES RELATED TO HIV INFECTION. 2021 , 80, 342-348		0
7	Low incidence of advanced neurological burden but high incidence of age-related conditions that are dementia risk factors in aging people living with HIV: a data-linkage 10-year follow-up study.		0
6	Performance of Cardiovascular Risk Prediction Models Among People Living With HIV.		1
5	Development and Validation of the HIV-CARDIO-PREDICT Score to Estimate the Risk of Cardiovascular Events in HIV-Infected Patients. 2023 , 12, 523		0

- 4 Direct and indirect cardiovascular and cardiometabolic sequelae of the combined anti-retroviral therapy on people living with HIV. 14, ○
- 3 Comparing implications of cardiovascular risk of abacavir and integrase inhibitors: why scientific community is confused and timid?. 2023, 37, 1005-1008 ○
- 2 Prediction models for cardiovascular disease risk among people living with HIV: A systematic review and meta-analysis. 10, ○
- 1 Association of Antiretroviral Therapy with Platelet Function and Systemic Inflammatory Response in People Living with HIV: A Cross-Sectional Study. 2023, 11, 958 ○